Lange, T., Ernst, T., Gruber, F. X., Maier, J., Cross, M., Müller, M. C., Niederwieser, D., Hochhaus, A. and Pfirrmann, M. (2013) “The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia”, Haematologica. Pavia, Italy, 98(5), pp. 714-717. doi: 10.3324/haematol.2012.068890.